Semax vs Selank: Side-by-Side Cognitive Peptide Comparison — Mechanism, Dose & Half-Life

Semax vs Selank head-to-head: mechanism differences, intranasal vs injectable administration, cognitive effect profiles, half-life comparison, and dosing notes for nootropic researchers.

TL;DR

• Semax is an analog of the ACTH4-7 neuropeptide with stimulating, pro-cognitive effects driven by BDNF upregulation, dopamine, and norepinephrine modulation
• Selank is a synthetic analog of the immune peptide tuftsin with anxiolytic and mood-stabilizing effects via GABA pathway modulation
• Both were developed and are approved in Russia; both are typically administered intranasally
• N-Acetyl variants of both peptides offer improved stability and potentially enhanced brain penetration
• Explore nootropic peptides → | Reconstitution Calculator →

⚠️ Disclaimer: This article is written for educational and research purposes only. Semax and Selank are not FDA-approved compounds in the United States and are not dietary supplements. Both are approved pharmaceutical drugs in Russia and some other countries. Nothing in this article constitutes medical advice. Consult a licensed healthcare professional before making any decisions regarding these compounds.

Cognitive peptide research occupies a unique space within the broader peptide science landscape. While most research compounds in the Western literature focus on metabolic, musculoskeletal, or endocrine endpoints, Russia's scientific establishment developed a distinct tradition of neuropeptide research beginning in the Soviet era that produced several compounds with remarkable central nervous system effects. Semax and Selank are the two most prominent products of this research tradition — both approved pharmaceutical medications in Russia, and both studied extensively for cognitive and neurological applications. For another cognitive peptide with a distinct mechanism, see the Dihexa research overview.

Despite some surface similarities — both are peptides, both are given intranasally, both affect brain function — Semax and Selank are mechanistically quite different, and they serve different research purposes. Semax is essentially a cognitive activator and neuroprotectant with a stimulating profile; Selank is an anxiolytic and stress-modulator with a calming profile. Understanding these differences is essential for selecting the appropriate compound for your specific research question.

Background: Russian Neuropeptide Research

The development of Semax and Selank grew from a decades-long research program at the Institute of Molecular Genetics and other Soviet and Russian academic institutions focused on the physiological roles of endogenous neuropeptides. The Soviet scientific establishment invested heavily in neuropeptide research during the 1970s and 1980s, reasoning that peptides derived from naturally occurring brain proteins would have fewer toxicity and side-effect concerns than synthetic small-molecule drugs.

Semax was developed specifically from the ACTH(4-7) fragment of adrenocorticotropic hormone — a region of ACTH that research had shown to have cognitive-enhancing effects independent of ACTH's classical endocrine function. Selank was engineered from tuftsin, a naturally occurring tetrapeptide produced from immunoglobulin G that had been shown to have anxiolytic properties in animal studies.

Both compounds completed clinical trials in Russia and received regulatory approval for specific indications: Semax for cognitive enhancement, stroke recovery, and attention disorders; Selank for anxiety treatment and immune modulation. This regulatory status gives them a more substantial human research base than many other peptides used in Western research contexts, though the Russian clinical literature is not always easily accessible or directly comparable to Western regulatory standards.

What Is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derived from the ACTH(4-10) fragment, with modifications that confer resistance to peptidase degradation and improve bioavailability. Its parent sequence, ACTH(4-7) — also called melanocyte-stimulating hormone release-inhibiting factor — was the original cognitive-active fragment identified in early research, and Semax extends this sequence while adding a proline residue for stability.

The primary mechanism through which Semax produces its cognitive effects is BDNF (brain-derived neurotrophic factor) upregulation. BDNF is one of the most important neuroprotective proteins in the brain, supporting the survival and growth of neurons, promoting synaptic plasticity, and playing a crucial role in learning and memory consolidation. Multiple studies have shown that Semax significantly increases BDNF expression in the hippocampus and frontal cortex — the brain regions most relevant to memory and executive function.

Beyond BDNF, Semax has been shown to influence the dopamine and norepinephrine neurotransmitter systems. It increases the sensitivity of dopaminergic and noradrenergic signaling in prefrontal circuits, which is consistent with its reported stimulating, attention-enhancing profile. This mechanism makes Semax particularly relevant to research on attention disorders, executive function, and cognitive fatigue.

Semax has also demonstrated significant neuroprotective activity in stroke and ischemia models, reducing the extent of neural damage following oxygen deprivation and accelerating functional recovery. Russian clinical use includes administration in the acute phase of ischemic stroke — a context that has driven much of the rigorous clinical investigation of the compound.

Typical research doses range from 0.1–1.0 mg/day (100–1,000 mcg/day) via intranasal administration. The 0.5% and 1% solution formulations are commonly used in clinical and research settings in Russia, which translate to approximately 50–100 mcg per drop depending on drop volume.

What Is Selank?

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg) — a tetrapeptide fragment of immunoglobulin G that plays roles in both immune function and central nervous system activity. Selank was developed by appending a stabilizing Pro-Gly-Pro sequence to the tuftsin core, improving its resistance to enzymatic degradation while enhancing central activity.

The primary mechanism of Selank's anxiolytic and mood-stabilizing effects appears to involve the GABAergic system. Research has shown that Selank modulates the expression and activity of GABA-A receptors, producing anxiolytic effects similar to benzodiazepines but through a less direct and potentially safer mechanism. Unlike benzodiazepines, Selank does not produce sedation, tolerance, or withdrawal effects at typical research doses — a significant practical advantage.

Selank also influences serotonin metabolism, increasing the expression and activity of enzymes involved in serotonin synthesis and breakdown. This serotonergic activity may contribute to its mood-stabilizing and antidepressant-adjacent effects reported in some research models. The compound has also been studied for its effects on the immune system, including modulation of T-cell function and interleukin expression — reflecting its tuftsin heritage.

In clinical research in Russia, Selank has been studied for generalized anxiety disorder, mixed anxiety-depression, and immune deficiency states. The anxiolytic effects appear to develop within the first few days of use and are maintained with continued administration without the tolerance development seen with GABA-modulating pharmaceuticals.

Typical research doses are 250–500 mcg/day via intranasal administration, often split into two applications. The standard formulation used clinically in Russia is a 0.15% solution.

Side-by-Side Comparison Table

Intranasal Reconstitution: Preparing Solutions for Nasal Administration

Both Semax and Selank are most commonly studied via intranasal administration, which bypasses first-pass hepatic metabolism and allows direct delivery to the central nervous system via the olfactory nerve pathway. Intranasal bioavailability for neuropeptides is generally considered superior to oral delivery, though still lower than direct injection.

Preparing an intranasal peptide solution requires careful concentration math to achieve a consistent dose per drop or per actuation:

Standard nasal drop volume is approximately 0.05 mL (50 microliters) per drop, though this varies with dropper design. Nasal spray actuators typically deliver a more consistent volume of 0.1 mL (100 microliters) per spray.

Example: Preparing a 0.1% Semax nasal solution for 200 mcg/day dosing:

• Target: 200 mcg per day via nasal drops, split into 2 × 100 mcg applications
• With a standard dropper delivering ~50 mcg per drop at 0.1% concentration (1 mg/mL), you'd need 2 drops per application
• To make a 1 mg/mL (0.1%) solution: dissolve 1 mg Semax in 1 mL sterile saline or bacteriostatic water
• This gives 1 mg/mL → 0.05 mL/drop × 1 mg/mL = 0.05 mg = 50 mcg per drop
• Two drops = 100 mcg per application, 4 drops/day = 200 mcg/day total

Example: Preparing a 0.15% Selank nasal solution for 250 mcg/day dosing:

• Target: 250 mcg/day, split into 2 applications of 125 mcg each
• Dissolve 1.5 mg Selank in 1 mL water: concentration = 1,500 mcg/mL (0.15%)
• At 50 mcg/drop: each drop = 75 mcg → approximately 1.7 drops per application (round to 2 drops for ~150 mcg per application)
• Alternatively, use a spray actuator delivering 0.1 mL: 0.1 mL × 1,500 mcg/mL = 150 mcg per spray — close to target

Intranasal solutions should be prepared fresh or stored at 4°C for no more than 7–14 days, as peptide stability in aqueous solution without preservative is more limited than in lyophilized form. Use sterile saline (0.9% NaCl, preservative-free) or bacteriostatic saline as your solvent for nasal applications. For guidance on solvent selection and reconstitution technique more broadly, see the peptide reconstitution calculator guide.

Use the Reconstitution Calculator → to determine concentration for your specific dose and dropper/spray volume.

N-Acetyl Variants

Both Semax and Selank are available in N-acetylated forms — N-Acetyl Semax (also called NA Semax) and N-Acetyl Selank (NA Selank). The acetyl group is added to the N-terminus of the peptide chain, which confers two practical benefits:

1. Improved enzymatic stability — N-terminal acetylation protects against aminopeptidase degradation, extending the active half-life of the peptide in nasal mucosa and potentially in CNS tissue.

2. Enhanced lipophilicity and membrane penetration — the acetyl modification increases the compound's ability to penetrate cell membranes and cross the blood-brain barrier via transcellular pathways.

Research comparing N-acetyl variants to their parent compounds suggests improved potency per unit dose, meaning lower doses may achieve equivalent effects. Some researchers use N-Acetyl Semax at half the dose of standard Semax as a starting point, though dose equivalency studies are limited and individual variability is significant.

N-Acetyl Semax Amidate (also known as NASSA or NA Semax Amidate) adds a further C-terminal amide modification, providing protection from carboxypeptidase degradation in addition to the N-terminal protection. This double-modified form is considered by many researchers to have the most favorable stability profile of the Semax analogs, though it is also the least studied in formal research.

Which to Choose for Your Research?

The choice between Semax and Selank ultimately comes down to the research question being investigated and the neurological phenotype of interest:

Choose Semax if your research involves cognitive enhancement, attention and focus mechanisms, neuroprotection models (especially ischemia or stroke), BDNF pathway research, or dopamine/norepinephrine system studies. Semax's stimulating profile also makes it relevant for fatigue, cognitive load, and sustained attention research.

Choose Selank if your research involves anxiety models, stress response, GABAergic system research, mood and affective state studies, or immune-neurological interactions. Selank's calming profile without sedation makes it particularly useful for anxiety models where you want anxiolytic effects without confounding sedation variables.

For combination research: Semax and Selank are sometimes used together in research protocols targeting both cognitive performance and anxiety, given their complementary mechanisms. The stimulating effects of Semax may be partially offset by Selank's anxiolytic activity, creating a profile closer to "alert calm" than either compound alone. If you're designing combination protocols, use the reconstitution calculator to prepare each solution independently and administer them separately to maintain dosing control.

Conclusion

Semax and Selank represent a fascinating and underexplored branch of peptide research: CNS-active compounds with validated mechanisms, clinical data from Russian regulatory programs, and a safety profile that compares favorably to most small-molecule neurological drugs. Their distinct mechanisms — Semax through BDNF and catecholamine pathways, Selank through GABAergic and serotonergic modulation — make them genuinely complementary tools for different research questions.

For researchers new to these compounds, the intranasal administration route requires some additional preparation compared to subcutaneous peptide injection, particularly around concentration math for consistent per-dose delivery. The reconstitution calculator can help you work through the arithmetic for any combination of vial size, target concentration, and delivery volume.

Frequently Asked Questions About Semax and Selank

Q: What is the difference between Semax and Selank? A: Semax is a stimulating cognitive peptide derived from the ACTH(4-10) fragment that works primarily by upregulating BDNF and enhancing dopamine/norepinephrine signaling — producing a focus-enhancing, neuroprotective profile. Selank is an anxiolytic peptide derived from the immune peptide tuftsin that works through GABA-A receptor modulation and serotonin metabolism — producing a calming, mood-stabilizing profile without sedation. Both are approved pharmaceutical drugs in Russia and are typically administered intranasally.

Q: Which is better for focus — Semax or Selank? A: Semax is generally the preferred compound for research targeting cognitive enhancement, focus, and attention, because its mechanism directly involves BDNF upregulation and dopamine/norepinephrine modulation in prefrontal circuits — the pathways most relevant to executive function and sustained attention. Selank's anxiolytic profile may indirectly support focus in high-stress or anxiety-dominated research models by reducing the cognitive interference of anxiety, but it is not a direct cognitive stimulant. Some researchers use both together to capture alerting effects from Semax balanced by Selank's anxiolytic activity.

Q: How do you take Semax intranasally? A: Semax is administered as a nasal drop or spray solution, most commonly at concentrations of 0.1% (1 mg/mL) or 0.5% (5 mg/mL). At 1 mg/mL with a standard dropper delivering approximately 50 mcg per drop, a 200 mcg/day dose requires 4 drops split across two daily applications. The solution is prepared by reconstituting lyophilized Semax in sterile saline or bacteriostatic saline. Intranasal solutions should be used within 7–14 days and stored at 4°C.

Q: What are N-Acetyl Semax and N-Acetyl Selank? A: N-Acetyl Semax and N-Acetyl Selank are modified forms of the parent peptides where an acetyl group is added to the N-terminus of the peptide chain. This modification improves resistance to aminopeptidase degradation (extending half-life in nasal mucosa), and increases lipophilicity to potentially enhance blood-brain barrier penetration. N-Acetyl variants are generally considered more potent per unit dose, with some researchers using them at approximately half the dose of the standard forms as a starting point.

Q: Can you stack Semax and Selank together? A: Yes, Semax and Selank are sometimes used together in research protocols targeting both cognitive performance and anxiety, exploiting their complementary and largely non-overlapping mechanisms. Semax's stimulating effects through dopaminergic pathways can be balanced by Selank's GABAergic calming activity, producing a profile described as "alert calm" — reduced anxiety without sedation alongside enhanced cognitive clarity. When designing combination protocols, each solution should be prepared and administered independently to maintain individual dosing control.

This content is provided for educational and research informational purposes only. Semax and Selank are approved pharmaceutical compounds in Russia but are not FDA-approved in the United States. Their legal status varies by jurisdiction. This article does not constitute medical advice, and no claims are made regarding therapeutic efficacy in humans.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions